Priority Lists
Protocol Posting of
Activations
Activation
A Randomized, Placebo-controlled, Double-blind Trial Evaluating the Effect of Exemestane in Clinical cT1-3NO-1MO Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy
Study Coordinator(s) | Laura F. Hutchins, M.D. |
Participants | CTSU |
Activation
A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy
Action Codes | IP, ER |
Study Coordinator(s) | Julie R. Gralow, M.D. |
Participants | CTSU |
Activation
A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Study Coordinator(s) | Julie R. Gralow, M.D. |
Participants | CTSU |
Activation
A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer
Study Coordinator(s) | Peter F. Roberts, M.D. |
Participants | CTSU |
Activation
A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel Versus Sequenced AC Followed by Paclitaxel Verus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer
Participants | CTSU |
Activation
A Phase III Comparison of Prophylactic Cranial Irradiation versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer
Study Coordinator(s) | Laurie E. Gaspar, M.D. |
Participants | CTSU |
Activation 11/1/02
An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers
Study Coordinator(s) | Robert B. Montgomery, M.D., Mary L. Disis, M.D. |
Participants | Limited: Institutions Listed on the Title Page |
Activation
Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
Study Coordinator(s) | Ronald B. Natale, M.D., David R. Gandara, M.D., Primo N. Lara, Jr., M.D., Heinz- Josef Lenz, M.D. |
Participants | Members, NCORP, Affiliates, Medical Oncologists, Pathologists, CTSU |
Closures
Permanent Closure: 11/15/02
Enhancing Well-Being During Breast Cancer Recurrence
Study Coordinator(s) | Carolyn C. Gotay, Ph.D., Carol M. Moinpour, Ph.D., Silvana Martino, D.O., Bonnie M. Taylor, Ph.D. |
Participants | Medical Oncologists, NCORP, Members |
Closure Date | 2002-11-15 |
Amendments, Revisions, Memoranda
Memorandum
A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with "No Evidence of Disease" after Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
Action Codes | IP, AC, ER |
Study Coordinator(s) | Kim A. Margolin, M.D. |
Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
Revision #1
Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology with Outcome in Early Stage Nonseminomatous Germ Cell Tumor
Study Coordinator(s) | Craig R. Nichols, M.D. |
Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons, Radiation Oncologists, Pathologists |
Revision #6
A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma.
Study Coordinator(s) | Amy D. Tiersten, M.D. |
Participants | NCORP, Members, Surgeons, Pathologists |
Memorandum
A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation
Study Coordinator(s) | Robert B. Livingston, M.D. |
Participants | Members, Medical Oncologists, Pathologists, Surgeons, NCORP |
Memorandum
A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen
Study Coordinator(s) | Silvana Martino, D.O. |
Memorandum
Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma
Study Coordinator(s) | Lawrence E. Flaherty, M.D., John A. Thompson, M.D., Ralph J. Tuthill, M.D., John Vetto, M.D., Vernon K. Sondak, M.D., Jeffrey A. Sosman, M.D. |
Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, ECOG, COG, US INSTITUTIONS ONLY |
Memorandum
A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-Cell Acute Lymphoblastic Leukemia (ALL)
Study Coordinator(s) | Steven E. Coutre, M.D., David R. Head, M.D., David H. Boldt, M.D., Marilyn L. Slovak, Ph.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists |
Revision #8
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
Study Coordinator(s) | Robert P. Whitehead, M.D. |
Participants | Members, NCORP |
Amendment #3
A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) In Patients with Malignant Pleural Mesothelioma
Study Coordinator(s) | Linda L. Garland, M.D., Michael Lobell, M.D. |
Participants | Members, NCORP, Medical Oncologists |
Memorandum
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients with Locally Advanced Unresected Pancreatic Adenocarcinoma
Study Coordinator(s) | William H. Isacoff, M.D. |
Participants | Members, NCORP |
Revision #13
Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III.
Study Coordinator(s) | L. Michael Glode, M.D., Maha H.A. Hussain, M.D., Gregory P. Swanson, M.D., David P. Wood Jr., M.D., Wael A. Sakr, M.D. |
Participants | Members, NCORP, Affiliates, UCOP, Medical Oncologists, Surgeons, Radiation Oncologists, Pathologists, EPP, CALGB, CTSU Institutions in the United States |
Memorandum
A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients with Refractory Multiple Myeloma
Study Coordinator(s) | Mohamad A. Hussein, M.D., James K. Weick, M.D. |
Participants | NCORP, Members |
Memorandum, Amendment #3
Lung Cancer Specimen Repository Protocol, Ancillary
Study Coordinator(s) | Wilbur A. Franklin, M.D., Paul H. Gumerlock, Ph.D., David R. Gandara, M.D. |
Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, NCIC-CTG, ECOG |
Amendment #2
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes, Phase III
Study Coordinator(s) | Lori J. Pierce, M.D. |
Participants | Medical Oncologists, Radiation Oncologists, Surgeons, NCCTG, RTOG, ACOSOG, ECOG, CALGB, NCORP, Members, NCIC-CTG, NSABP |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required